Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China · Delayed Price · Currency is CNY 6.41
-0.49 (-7.10%)
Feb 3, 2026, 3:04 PM CST
Beijing SL Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 570.93 | 652.74 | 1,005 | 1,033 | 1,199 | 1,093 |
Other Revenue | 7.68 | 7.68 | 12.98 | 17.05 | 16.05 | 20.21 |
| 578.61 | 660.42 | 1,018 | 1,050 | 1,215 | 1,113 | |
Revenue Growth (YoY) | -26.04% | -35.15% | -3.03% | -13.55% | 9.17% | -45.18% |
Cost of Revenue | 217.48 | 212.09 | 188.81 | 156.96 | 183.57 | 167.71 |
Gross Profit | 361.13 | 448.33 | 829.55 | 893.21 | 1,031 | 945.02 |
Selling, General & Admin | 257.66 | 259.91 | 405.65 | 546.76 | 585.32 | 588.56 |
Research & Development | 125.8 | 149.62 | 177.11 | 161.65 | 196.15 | 188.64 |
Other Operating Expenses | -0.09 | 1.66 | 2.89 | 9.2 | 11.22 | 12.03 |
Operating Expenses | 380.35 | 420.68 | 609.45 | 749.55 | 818.94 | 795.07 |
Operating Income | -19.22 | 27.65 | 220.1 | 143.66 | 212.3 | 149.95 |
Interest Expense | - | - | - | -0.1 | -0.23 | -0.35 |
Interest & Investment Income | 12.31 | 21.52 | 48.46 | 93.84 | 112.26 | 73.5 |
Currency Exchange Gain (Loss) | -0.9 | -0.9 | 0.7 | 0.02 | 0.05 | 0.04 |
Other Non Operating Income (Expenses) | 3.87 | -1.66 | -1.83 | -0.21 | -0.23 | -0.27 |
EBT Excluding Unusual Items | -3.94 | 46.61 | 267.44 | 237.21 | 324.14 | 222.86 |
Gain (Loss) on Sale of Investments | 77.03 | -172.29 | 205.21 | 19.49 | 113.58 | 176.41 |
Gain (Loss) on Sale of Assets | 0 | 0 | 0.01 | 0.21 | 3.22 | -0 |
Asset Writedown | - | - | - | -0 | -0.02 | -0.02 |
Other Unusual Items | -10.81 | -8.07 | -7.76 | 2.45 | 16.91 | 13.53 |
Pretax Income | 62.28 | -133.75 | 464.89 | 259.35 | 457.84 | 412.78 |
Income Tax Expense | -20.81 | -58.46 | 49.94 | 31.01 | 36.51 | 51.33 |
Earnings From Continuing Operations | 83.09 | -75.29 | 414.96 | 228.34 | 421.33 | 361.45 |
Minority Interest in Earnings | 0.68 | 1.22 | 1.73 | 6.06 | 4.61 | 3.26 |
Net Income | 83.77 | -74.07 | 416.69 | 234.4 | 425.94 | 364.71 |
Net Income to Common | 83.77 | -74.07 | 416.69 | 234.4 | 425.94 | 364.71 |
Net Income Growth | 1.68% | - | 77.77% | -44.97% | 16.79% | -25.08% |
Shares Outstanding (Basic) | 1,059 | 1,058 | 1,016 | 1,019 | 1,039 | 1,013 |
Shares Outstanding (Diluted) | 1,059 | 1,058 | 1,016 | 1,019 | 1,039 | 1,013 |
Shares Change (YoY) | 4.23% | 4.11% | -0.28% | -1.90% | 2.55% | -2.19% |
EPS (Basic) | 0.08 | -0.07 | 0.41 | 0.23 | 0.41 | 0.36 |
EPS (Diluted) | 0.08 | -0.07 | 0.41 | 0.23 | 0.41 | 0.36 |
EPS Growth | -2.45% | - | 78.26% | -43.90% | 13.89% | -23.40% |
Free Cash Flow | -285.7 | -121.89 | 241.84 | 226.33 | 227.72 | 159.89 |
Free Cash Flow Per Share | -0.27 | -0.12 | 0.24 | 0.22 | 0.22 | 0.16 |
Dividend Per Share | 0.020 | 0.020 | 0.150 | 0.100 | 0.100 | 0.100 |
Dividend Growth | -86.67% | -86.67% | 50.00% | - | - | -50.00% |
Gross Margin | 62.41% | 67.89% | 81.46% | 85.05% | 84.89% | 84.93% |
Operating Margin | -3.32% | 4.19% | 21.61% | 13.68% | 17.48% | 13.48% |
Profit Margin | 14.48% | -11.21% | 40.92% | 22.32% | 35.06% | 32.78% |
Free Cash Flow Margin | -49.38% | -18.46% | 23.75% | 21.55% | 18.75% | 14.37% |
EBITDA | 139.38 | 180.59 | 365.5 | 257.17 | 311.97 | 239.44 |
EBITDA Margin | 24.09% | 27.34% | 35.89% | 24.49% | 25.68% | 21.52% |
D&A For EBITDA | 158.6 | 152.94 | 145.4 | 113.51 | 99.67 | 89.49 |
EBIT | -19.22 | 27.65 | 220.1 | 143.66 | 212.3 | 149.95 |
EBIT Margin | -3.32% | 4.19% | 21.61% | 13.68% | 17.48% | 13.48% |
Effective Tax Rate | - | - | 10.74% | 11.96% | 7.98% | 12.43% |
Revenue as Reported | 578.61 | 660.42 | 1,018 | 1,050 | 1,215 | 1,113 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.